Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) has been given a consensus rating of "Buy" by the seven analysts that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.40.
Several analysts have commented on CRDL shares. HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research note on Monday. Rodman & Renshaw assumed coverage on Cardiol Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $7.00 price objective on the stock. Finally, RODMAN&RENSHAW raised Cardiol Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 28th.
Check Out Our Latest Research Report on CRDL
Institutional Trading of Cardiol Therapeutics
Several large investors have recently modified their holdings of CRDL. Jones Financial Companies Lllp purchased a new position in Cardiol Therapeutics in the fourth quarter worth about $25,000. Townsquare Capital LLC bought a new position in shares of Cardiol Therapeutics in the 3rd quarter worth approximately $27,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Cardiol Therapeutics in the third quarter worth approximately $27,000. Jane Street Group LLC bought a new stake in Cardiol Therapeutics during the third quarter valued at approximately $29,000. Finally, Cetera Investment Advisers bought a new stake in Cardiol Therapeutics during the fourth quarter valued at approximately $56,000. Institutional investors own 12.49% of the company's stock.
Cardiol Therapeutics Stock Down 5.6 %
Shares of NASDAQ:CRDL traded down $0.07 during trading on Friday, reaching $1.11. 275,596 shares of the stock traded hands, compared to its average volume of 268,816. The stock has a market cap of $91.28 million, a P/E ratio of -2.81 and a beta of 0.91. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49. The stock has a 50-day moving average of $1.31 and a two-hundred day moving average of $1.68. Cardiol Therapeutics has a 52-week low of $1.06 and a 52-week high of $3.12.
Cardiol Therapeutics Company Profile
(
Get Free ReportCardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Articles
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
